VIVITROL 380MG
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $918,485 | 44 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $918,485 | 44 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of Naltrexone for use in Conjunction with BUPRENORPHINE in Adults with Opioid Use Disorder Transitioning from BUPRENORPHINE Maintenance Prior to First Dose of VIVITROL | Alkermes, Inc. | $918,485 | 0 |
Top Doctors Receiving Payments for VIVITROL 380MG
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Hinsdale, IL | $918,485 | 44 |
Manufacturing Companies
- Alkermes, Inc. $918,485
Product Information
- Type Drug
- Total Payments $918,485
- Total Doctors 0
- Transactions 44
About VIVITROL 380MG
VIVITROL 380MG is a drug associated with $918,485 in payments to 0 healthcare providers, recorded across 44 transactions in the CMS Open Payments database. The primary manufacturer is Alkermes, Inc..
Payment data is available from 2018 to 2018. In 2018, $918,485 was paid across 44 transactions to 0 doctors.
The most common payment nature for VIVITROL 380MG is "Unspecified" ($918,485, 100.0% of total).
VIVITROL 380MG is associated with 1 research study, including "A Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of Naltrexone for use in Conjunction with BUPRENORPHINE in Adults with Opioid Use Disorder Transitioning from BUPRENORPHINE Maintenance Prior to First Dose of VIVITROL" ($918,485).